Targeted Therapies and Cancer Vaccines Advance in Parallel as More Than 30 Innovative Cancer Drugs Approved in China This Year

So far this year, more than 30 innovative cancer drugs have been approved in China. Targeted therapies continue to address previously hard-to-treat targets such as KRAS G12C, EGFR exon 20 insertions, NTRK, FGFR and MET, making targeted treatment increasingly accessible. Meanwhile, the cancer vaccine sector is also accelerating. Industry observers say targeted drug targets have been well validated, and the field has entered a stage of commercialization and homogeneous competition; cancer vaccines remain at the frontier of exploration and clinical validation. The industry is optimistic about the synergy between the two: while targeted drugs shrink tumors, cancer vaccines work through active immune mechanisms, and combination therapy may improve treatment outcomes. However, whether the large number of vaccine candidates can successfully pass Phase II/III clinical validation remains highly uncertain. (Economic Reference Daily)